
Cooper Cos (COO) Stock
Global contact lens and fertility products maker. Here's the price, business snapshot, and what's worth knowing about Cooper Cos in November 2026.
CooperCompanies (ticker: COO) is a global healthcare company best known for two businesses: CooperVision, a leading maker of soft contact lenses, and CooperSurgical, which supplies fertility, gynaecology and surgical products. CooperVision generates recurring revenue through contact lens replacement cycles and a broad product range across daily, monthly and speciality lenses, while CooperSurgical adds exposure to the women’s health and fertility care markets. The business has a meaningful international footprint and benefits from demographic trends, rising vision correction demand and expanding access to fertility services. Key growth drivers include product innovation, expanded distribution (including online channels), and expansion into emerging markets. Investors should weigh these opportunities against risks such as competitive pressures, regulatory approval and reimbursement dynamics, currency headwinds and supply-chain exposure. This summary is for general, educational purposes only and is not personalised investment advice; values can rise and fall and past performance does not predict future results.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cooper Companies' stock, with a target price suggesting significant potential growth.
Financial Health
Cooper Companies is performing well with strong revenue and profit margins, but cash flow is modest.
Dividend
Cooper Cos Inc has a low dividend yield of 0.04%, indicating limited returns for dividend-seeking investors. If you invested $1000 you would be paid $0.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring revenue model
Contact lenses create repeat purchases and predictable revenue from replacement cycles, though sales can vary with competition and consumer trends.
Global market exposure
Broad international reach provides growth opportunities as vision care and fertility services expand, while also introducing currency and regional risks.
Product innovation focus
Investment in new lens technologies and fertility solutions can drive share gains, yet regulatory approvals and R&D outcomes are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.